The last time we mentioned Viking Therapeutics (VKTX), we said:
“While the obesity drug stock has already exploded, it could see higher highs. At the moment, Viking Therapeutics and its potential treatment for obesity – VK2735, has already shown a mean weight loss of up to 18 pounds from baseline. The company also initiated Phase 1 clinical study to evaluate a novel oral formulation of VK2735.”
That was on February 20, as VKTX traded at around $35. Today, it’s up to $37.42 and we still strongly believe it could see higher highs.
Should VKTX see even better results, it could be exposed to a significant opportunity.
Remember, the obesity story is bursting at the seams.
According to the World Health Organization, obesity has tripled since 1975. More than 1.9 billion adults were overweight as of 2016, with more than 650 million considered obese. Plus, more than 340 million children were considered overweight in 2016 as well.
However, if millions of people can take a pill or get a shot to help lose weight, it could create an unbelievable opportunity for VKTX – just as it has for other related companies.
